| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | RECRUITING | PHASE3 | 2024-10-02 | 2028-07 | 2026-11 |
| NCT06345404 | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD | RECRUITING | PHASE1 | 2024-04-23 | 2025-11 | 2025-10 |
| NCT04734873 | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients | TERMINATED | PHASE3 | 2021-02-25 | 2021-08-18 | 2021-08-18 |
| NCT04464395 | Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients | COMPLETED | PHASE1 | 2020-07-01 | 2021-07-09 | 2021-03-01 |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE1 | 2020-02-20 | 2022-03-01 | 2021-09-21 |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-05-03 | 2026-04-30 | 2026-04-30 |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | COMPLETED | PHASE1 | 2018-04-25 | 2023-02-19 | 2022-12-28 |
| NCT03237988 | Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects | COMPLETED | PHASE1 | 2017-07-20 | 2017-10-04 | 2017-09-20 |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | COMPLETED | PHASE1 | 2016-01 | 2021-07 | 2021-06 |